Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Haleos Labs Limited
Quarter-by-quarter operating performance
| Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 88.29 | 63.73 | 74.65 | 69.26 | 72.05 | 89.99 | 92.55 | 78.46 | 84.60 | 89.11 | 82.50 | 81.37 | 94.78 |
| Expenses + | 78.92 | 61.45 | 72.11 | 61.33 | 62.75 | 78.63 | 76.27 | 69.89 | 71.85 | 81.69 | 70.79 | 67.79 | 80.73 |
| Operating Profit | 9.37 | 2.28 | 2.54 | 7.93 | 9.30 | 11.36 | 16.28 | 8.57 | 12.75 | 7.42 | 11.71 | 13.58 | 14.05 |
| OPM % | 10.61% | 3.58% | 3.40% | 11.45% | 12.91% | 12.62% | 17.59% | 10.92% | 15.07% | 8.33% | 14.19% | 16.69% | 14.82% |
| Other Income + | 0.49 | 4.81 | 0.61 | 0.27 | 0.58 | 2.36 | 0.44 | 2.04 | 0.06 | 2.34 | 1.00 | 0.42 | 0.18 |
| Interest | 1.67 | 1.80 | 2.18 | 2.81 | 2.34 | 2.84 | 2.40 | 2.14 | 2.14 | 2.03 | 1.87 | 1.62 | 1.54 |
| Depreciation | 2.63 | 2.92 | 3.70 | 3.73 | 3.73 | 3.78 | 3.68 | 3.76 | 3.76 | 3.80 | 3.82 | 3.89 | 3.91 |
| Profit before tax | 5.56 | 2.37 | -2.73 | 1.66 | 3.81 | 7.10 | 10.64 | 4.71 | 6.91 | 3.93 | 7.02 | 8.49 | 8.78 |
| Tax % | 31.29% | 10.55% | 40.29% | 126.51% | -8.14% | 8.73% | 33.27% | 29.72% | 29.81% | 11.45% | 37.61% | 24.38% | 24.26% |
| Net Profit + | 3.82 | 2.11 | -3.83 | -0.44 | 4.12 | 6.47 | 7.10 | 3.30 | 4.86 | 3.48 | 4.39 | 6.42 | 6.65 |
| EPS in Rs | 13.20 | 5.66 | -5.95 | 2.25 | 14.22 | 19.52 | 23.15 | 15.45 | 18.09 | 9.82 | 13.76 | 20.18 | 21.90 |
Financials of Haleos Labs Limited
Annual income statement trend
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales + | 378 | 261 | 266 | 350 | 316 | 306 | 345 | 348 |
| Expenses + | 343 | 235 | 235 | 316 | 287 | 275 | 300 | 301 |
| Operating Profit | 35 | 25 | 30 | 35 | 29 | 31 | 45 | 47 |
| OPM % | 9% | 10% | 11% | 10% | 9% | 10% | 13% | 13% |
| Other Income + | 2 | 2 | 2 | 14 | 5 | 4 | 5 | 4 |
| Interest | 6 | 5 | 5 | 6 | 7 | 10 | 9 | 7 |
| Depreciation | 6 | 8 | 8 | 10 | 11 | 15 | 15 | 15 |
| Profit before tax | 25 | 15 | 20 | 33 | 17 | 10 | 26 | 28 |
| Tax % | 30% | 31% | 31% | 23% | 31% | 36% | 28% | |
| Net Profit + | 18 | 10 | 14 | 25 | 11 | 6 | 19 | 21 |
| EPS in Rs | 59.04 | 33.67 | 44.85 | 83.75 | 37.91 | 30.07 | 66.52 | 65.66 |
| Dividend Payout % | 3% | 0% | 3% | 2% | 4% | 5% | 2% |
Financials of Haleos Labs Limited
Capital structure and asset base
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves | 103 | 113 | 126 | 149 | 166 | 174 | 194 | 203 |
| Borrowings + | 47 | 65 | 65 | 80 | 100 | 101 | 86 | 70 |
| Other Liabilities + | 116 | 72 | 108 | 125 | 126 | 114 | 107 | 118 |
| Total Liabilities | 270 | 253 | 302 | 357 | 395 | 391 | 390 | 394 |
| Fixed Assets + | 118 | 124 | 130 | 142 | 228 | 223 | 232 | 226 |
| CWIP | 3 | 16 | 38 | 51 | 1 | 6 | 0 | 9 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 148 | 113 | 134 | 164 | 166 | 162 | 158 | 159 |
| Total Assets | 270 | 253 | 302 | 357 | 395 | 391 | 390 | 394 |
Financials of Haleos Labs Limited
Operating, investing and financing cash movement
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 30 | 15 | 35 | -11 | 15 | 24 | 34 |
| Cash from Investing Activity + | -44 | -27 | -26 | -7 | -31 | -18 | -15 |
| Cash from Financing Activity + | 15 | 12 | -3 | 11 | 17 | -7 | -19 |
| Net Cash Flow | 1 | -0 | 6 | -8 | 0 | -1 | -0 |
| Free Cash Flow | 6 | -9 | -0 | -53 | -28 | 4 | 19 |
| CFO/OP | 105% | 69% | 133% | -10% | 62% | 88% | 94% |
Financials of Haleos Labs Limited
Working capital efficiency and return ratios
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 40 | 30 | 47 | 35 | 53 | 61 | 73 |
| Inventory Days | 116 | 149 | 164 | 159 | 184 | 196 | 160 |
| Days Payable | 140 | 101 | 163 | 146 | 127 | 143 | 126 |
| Cash Conversion Cycle | 16 | 78 | 48 | 48 | 110 | 115 | 106 |
| Working Capital Days | 14 | 18 | 2 | 17 | 24 | 11 | 7 |
| ROCE % | 12% | 13% | 12% | 8% | 7% | 12% |
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…